The scientific community does not even know yet if the virus is completely eradicated or simply held in check at an undetectable assay level. (I believe it is eradicated, but, that is irrelevant for this exercise.)
How is it irrelevant? It is, in fact, one of the two key points. I believe there is very compelling data that it is not irradicated - and thus the only mechanism for control is if the immune system recognizes it. It isn't clear that just lowering the viral load will get the same immune system recognition that using ifn will get.
Additionally, how would you account for the non-IFN drugs working as a monotherapy?
You must be posting backwards in time - there are no large non-ifn monotherapy trial results in 2009. All of them have either concurrent ifn or subsequent ifn at this point.
Market Data 
Markets 
AI
